V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10473299 | 10042418 | 1.62 | 56 | 03 | 2019-04-10 | 2019-04-10 | Cisplatin + Etoposide po&iv 3 day | 02 | N | BORTEZOMIB + DARATUMUMAB | 101188466 |
| 10473367 | 10042421 | 1.65 | 86.6 | Curative (C) | 2017-12-08 | 2017-12-22 | CTD | 02 | N | IRINOTECAN + MDG | 101429359 |
| 10473373 | 10042422 | 1.66 | 71.4 | Palliative (P) | 2017-05-18 | 2017-06-08 | AVELUMAB + AXITINIB | 02 | N | AC | 100150533 |
| 10473777 | 10042428 | 0 | 61.55 | Palliative (P) | 2020-07-11 | 2020-07-25 | CABOZANTINIB | 02 | N | TRASTUZUMAB | 101465874 |
| 10473871 | 10042430 | 1.78 | 98 | Adjuvant (A) | 2018-12-26 | 2018-12-26 | Carboplatin + Paclitaxel + Pembrolizumab | N | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100566143 |
| 10473890 | 10042431 | 1.79 | 76 | 03 | 2019-07-27 | 2019-08-03 | Liposomal Doxorubicin 50mg/m2 | 02 | N | THALIDOMIDE | 100858177 |
| 10473954 | 10042433 | 1.74 | 0 | Palliative (P) | 2018-11-13 | 2018-11-14 | BENDAMUSTINE + THALIDOMIDE | 02 | N | PACLITAXEL + TRASTUZUMAB | 100472531 |
| 10473982 | 10042434 | 1.71 | 82 | Adjuvant (A) | 2019-01-04 | 2019-01-04 | CISPLATIN + ETOPOSIDE | 02 | N | STAMPEDE TRIAL | 100054820 |
| 10474251 | 10042437 | null | null | null | 2022-03-18 | 2022-03-18 | Cetuximab + FLUOROURACIL + FOLINIC ACID + OXALIPLATIN | 02 | null | LANREOTIDE | 100075128 |
| 10474443 | 10042440 | 1.72 | 60.2 | null | 2018-07-12 | 2018-07-12 | ECX | 99 | null | FLAIR TRIAL | 100039506 |
| 10474469 | 10042441 | 1.62 | 60.1 | Palliative (P) | 2020-11-29 | 2020-12-06 | STAMPEDE TRIAL | 02 | null | RIBOCICLIB | 100592980 |
| 10474518 | 10042442 | 1.75 | 85 | Palliative (P) | 2019-03-08 | 2019-03-19 | Obinutuzumab + Venetoclax | 02 | N | FLUDARABINE + MELPHALAN | 100491764 |
| 10474535 | 10042444 | 1.85 | 0 | Neo-adjuvant (N) | 2020-09-10 | 2020-09-11 | IDELALISIB + RITUXIMAB | 02 | N | CISPLATIN + RT | 100912857 |
| 10474622 | 10042445 | 1.9 | 73.9 | 03 | null | 2017-03-18 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | null | N | AZACITIDINE + VENETOCLAX | 101012081 |
| 10474629 | 10042446 | 1.67 | 84.5 | Disease modification (D) | 2018-08-16 | 2018-08-18 | Ribociclib | 02 | N | AZACITIDINE + VENETOCLAX | 101656894 |
| 10474716 | 10042447 | 1.69 | 61.8 | Disease modification (D) | 2019-04-12 | 2019-04-12 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | N | N | CABOZANTINIB | 101208441 |
| 10474890 | 10042450 | 1.76 | 95.5 | null | 2022-02-28 | 2022-02-28 | PACLITAXEL + TRASTUZUMAB | 02 | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101623311 |
| 10475044 | 10042452 | 1.8 | 77.3 | Curative (C) | 2019-01-16 | 2019-01-17 | null | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 101520899 |
| 10475200 | 10042456 | 1.54 | 79 | Curative (C) | null | 2018-07-20 | LANREOTIDE | N | null | CYTARABINE + VENETOCLAX | 100329557 |
| 10475358 | 10042457 | null | null | Palliative (P) | 2020-11-27 | 2020-12-11 | null | 02 | null | AML19 TRIAL | 101297316 |
| 10475393 | 10042459 | 1.84 | 64.1 | Adjuvant (A) | 2018-08-30 | 2018-09-03 | null | 02 | Y | OBINUTUZUMAB + VENETOCLAX | 101777741 |
| 10475604 | 10042461 | 0 | 68.1 | Palliative (P) | 2019-09-13 | 2019-12-06 | null | null | null | VINORELBINE | 100560941 |
| 10475662 | 10042463 | 1.76 | 79 | Curative (C) | 2015-02-10 | 2019-10-03 | null | 02 | N | APALUTAMIDE | 100322867 |
| 10475962 | 10042466 | 1.77 | 96 | 03 | 2019-03-29 | 2019-03-29 | Thalidomide 50mg | 02 | null | VEDEX | 101027881 |
| 10476164 | 10042467 | 1.62 | 78 | null | 2020-04-08 | 2020-04-08 | Bortezomib + Panobinostat | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101754420 |
| 10476258 | 10042468 | 1.66 | 0 | Palliative (P) | 2017-09-02 | 2017-09-09 | AZACITIDINE + VENETOCLAX | 02 | N | MPT | 101228673 |
| 10476261 | 10042469 | 1.72 | 76 | Disease modification (D) | 2018-08-29 | 2018-09-02 | CISPLATIN + ETOPOSIDE | 99 | N | AZACITIDINE + VENETOCLAX | 100882072 |
| 10476353 | 10042470 | 1.84 | 84 | Curative (C) | 2016-05-04 | 2021-02-05 | Vemurafenib | 02 | null | THALIDOMIDE | 101118411 |
| 10476392 | 10042472 | 1.62 | 82 | 03 | 2020-06-06 | 2020-06-13 | CARBOPLATIN + FLUOROURACIL | 02 | Y | AVELUMAB + AXITINIB | 100938357 |
| 10476402 | 10042473 | 1.73 | null | Palliative (P) | 2017-07-15 | 2017-07-28 | BLEOMYCIN | 02 | N | IDELALISIB + RITUXIMAB | 100339750 |
| 10476448 | 10042474 | 1.63 | 75.8 | Palliative (P) | 2018-04-22 | 2018-05-01 | AVAPRITINIB | 02 | N | FEC | 101290882 |
| 10476503 | 10042476 | 166 | 74.3 | 03 | 2021-01-16 | 2021-05-05 | SCALOP-2 Trial | 02 | N | BORTEZOMIB + DARATUMUMAB | 100079048 |
| 10476536 | 10042477 | null | null | Palliative (P) | 2018-03-27 | 2018-04-01 | Sorafenib | 02 | N | BENDAMUSTINE + OFATUMUMAB | 101716424 |
| 10476616 | 10042479 | 1.79 | 66.8 | Curative (C) | 2021-11-14 | 2021-11-15 | MASITINIB | 02 | null | TRABECTEDIN | 100313512 |
| 10476633 | 10042480 | 1.94 | 73 | 03 | 2015-08-08 | 2016-03-15 | FEC + DOCETAXEL | 02 | N | VEMURAFENIB | 101763749 |
| 10476699 | 10042481 | 1.49 | 60.6 | 03 | null | 2016-11-15 | AVELUMAB + AXITINIB | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101630583 |
| 10476731 | 10042482 | null | 82 | Curative (C) | null | 2018-05-16 | Doxorubicin chemoembolisation | null | Y | ANAGRELIDE | 101747177 |
| 10476753 | 10042485 | null | null | Palliative (P) | 2018-03-11 | 2018-04-09 | Vemurafenib | N | N | CABOZANTINIB | 101304677 |
| 10476809 | 10042488 | 1.77 | 70.2 | 03 | 2019-12-04 | 2019-12-08 | null | N | null | BORTEZOMIB + PANOBINOSTAT | 100367528 |
| 10476822 | 10042489 | 1.93 | 74 | Palliative (P) | 2017-12-26 | 2018-01-08 | Fulvestrant + Palbociclib | 02 | N | FLAG + IDARUBICIN | 101273115 |
| 10477017 | 10042494 | 1.51 | 85.3 | Palliative (P) | null | 2021-05-08 | CHLORAMBUCIL + OFATUMUMAB | 01 | null | IDELALISIB + RITUXIMAB | 101585803 |
| 10477134 | 10042495 | 1.64 | 78.5 | Neo-adjuvant (N) | 2016-04-06 | 2016-04-06 | IDELALISIB + RITUXIMAB | N | N | CISPLATIN + ETOPOSIDE | 100552561 |
| 10477144 | 10042496 | 0 | null | null | 2018-06-05 | 2018-06-11 | null | 02 | null | DOXORUBICIN | 101169350 |
| 10477187 | 10042498 | 1.58 | 50.9 | null | 2017-09-10 | 2017-09-10 | Vinorelbine (oral) | 02 | null | FEC + DOCETAXEL | 101650732 |
| 10477194 | 10042499 | 1.66 | 69.5 | null | 2018-03-14 | 2018-03-24 | CISPLATIN + ETOPOSIDE | 02 | null | TRASTUZUMAB | 101773435 |
| 10477213 | 10042501 | 1.68 | 64.2 | null | 2019-11-28 | 2019-12-18 | GDP | 02 | null | MELPHALAN + THALIDOMIDE | 101390086 |
| 10477510 | 10042504 | 1.68 | 41.3 | Curative (C) | null | 2019-08-01 | CHLORAMBUCIL + OFATUMUMAB | 2 | N | BINIMETINIB + ENCORAFENIB | 101182141 |
| 10477542 | 10042505 | 1.9 | 62.6 | Palliative (P) | 2018-03-05 | 2018-03-20 | ENRICH Trial | 02 | N | IXAZOMIB + LENALIDOMIDE | 100288084 |
| 10477608 | 10042509 | 1.85 | 0 | Palliative (P) | 2019-01-24 | 2019-02-01 | Doxorubicin chemoembolisation | 02 | N | STAMPEDE TRIAL | 100258500 |
| 10477696 | 10042511 | 1.65 | 76.9 | Disease modification (D) | 2017-05-11 | 2017-05-30 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | Y | LANREOTIDE | 101247612 |